Here, to develop an anti-tumor reagent, we designed human PLOD3-specific short interfering (si)RNAs to knockdown the endogenous PLOD3 overexpression in lung cancer and then investigate cell proliferation and cell death. Here, PLOD3 is linked to neoplasm.